Clinical Research Studies
We do research across every area of cardiovascular care. Our research offers hope for patients, options to discuss with your doctor, and opportunities to make a difference for future patients. See the search below for a list of our active and enrolling clinical research studies and see if you may qualify to participate.
Benefits of Research
Be More Active
Take a more active role in your own health care.
Potential to Unlock More Options
You may gain access to investigational treatments and medications.
Make a Contribution
Help find a new and better way to treat people with your condition.
Search for research studies
NanoCorStudy Investigator:
Jay Traverse, MD
About the Study:This is a Phase 1, prospective, multi-center, open-label, sequential dose escalation study to explore the safety, feasibility, and efficacy of a single intracoronary infusion of BNP116.sc-CMV.I1c in patients with NYHA Class III heart failure. Patients with symptomatic congestive heart failure will be enrolled until up to 12 subjects have received infusions of investigational product. All patients will be followed until 12 months post treatment intervention, and then undergo long-term follow-up via semi-structured telephone questionnaires every 6 months for an additional 24 months (+/- 30 days). Condition:
Heart Failure
|
View Study |
SOLVE-CRTStudy Investigator:
Jay Sengupta, MD
About the Study:This study is a prospective, multi-center, pivotal trial to study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy. The WiSE-CRT System is an implantable cardiac pacing system capable of delivering pacing energy to the left ventricle of the heart without using a pacing lead. Condition:
Heart Failure
|
View Study |
ATTR CMStudy Investigator:
Mosi Bennett, MD
About the Study:To evaluate the efficacy of AKCEA-TTR-LRx compared to placebo for 120 weeks in patients with ATTR-CM receiving available standard of care (SoC). Condition:
Cardiomyopathy
|
View Study |
TIMI 68Study Investigator:
Mosi Bennett, MD
About the Study:This is an international, multicenter, parallel-group, randomized, double-blind, placebo-controlled trial in patients with heart failure with reduced ejection fraction (left ventricular ejection fraction [LVEF] ≤40%) who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin versus placebo on the clinical outcome of cardiovascular death or worsening heart failure. Condition:
Heart Failure
|
View Study |
TAMBE AAAStudy Investigator:
Jesse Manunga, MD
About the Study:Prospective, non-randomized, multicenter study with two independent arms: 1) Primary Study Arm - TAAA and Pararenal aneurysms requiring only TAMBE System. Hypothesis-driven analysis. 2) Secondary Study Arm - TAAA requiring TAMBE System and CTAG Device(s). Non hypothesis-driven analysis. Condition:
Other
|
View Study |